Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Mr. Michael Withrow

Market Cap

5.68 Million CAD

Sector

Healthcare

Website

https://www.arevlifesciences.com

Description

AREV Life Sciences Global Corp.

Read More

Overview

Value

1

Growth

27

Health

13

Management

70

Analyst Opinion

46

Total

31

All Scores Out Of 100

Best Features

  • Earnings growth has improved recently
  • Has a low level of debt
  • Low preportion of income is paid as dividend

Risk Factors

  • Overvalued on cashflow basis
  • Income is not covering expenditure and investment
  • Earnings are negative
  • There is a history of diluting shareholders
  • 0
  • Does not hold enough liquid assets to cover short term liabilities
  • Poor overall financial health
  • No margin of safety at their current market price
  • Poor earnings and cashflow growth
  • 0

Market Peers

AREV.CN

Key Figures

PE Ratio (TTM)

N/A

Margin Of Safety (DCF)

-126.50%

Revenue Growth (5 Year Average)

N/A

Ratings Consensus

Sell

Share Buybacks

-10.31%

Dividend Yeild (TTM)

N/A

Valuation

Value Score

1

  • Estimated intrinsic-value of NaN undefined CAD is lower than current price ( 180.00 undefined CAD)
  • Free-cashflow-yeild of -7.32% is worse than the market average (4.7%)
  • Margin-of-safety of -126.50% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: N/A

Current Price: 0.2 CAD

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

N/Ax

Free Cashflow Yeild

-7.32%

PE/Earnings Growth

N/A

Price/Book

-6.72x

Growth

Growth Score

27

  • Revenue growth has improved this yeara
  • Earnings growth has improved this year
  • Free Cashflow growth has improved this year
  • 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
  • 5 Year Average Earnings growth of N/A is lower than the market average (14.48%)
  • 5 Year Average Free Cashflow growth of 7.58% is lower than the market average (12.35%)

Revenue Growth

N/A

Earnings Growth

N/A

Cashflow Growth

7.58%

Health

Health Score

13

  • Has a low level of debt
  • Normal operation does not require debt to be sustainable
  • Cashflow is negative
  • 0
  • Assets do not cover liabilities
  • Debt repayments significantly impact cashflow

Altman Z Score

N/A

Piostroski Score

4.00

Debt/Equity

N/Ax

Current Assets/Liabilities

0.11x

Free Cashflow/Total Debt

N/Ax

Debt/Capital

0.38x

Management

Management Score

70

  • Has issued new shares to finance growth when share price is high
  • Return-on-equity of 37.35% is higher than the market average (15%)
  • Return-on-capital-employed of -10.99% is lower than the market average (10%)
  • Has a history of diluting shareholders to finance activity

Average Buybacks/Dilution

-10.31%

Recent Buybacks/Dilution

3.18%

5 Year Price Volitility

123.80%

Return On Assets

-87.42%

Return On Capital Employed

-10.99%

Return On Equity

37.35%

Return On Free Cashflow

188.66%

Return On Investments

N/A

Analysts

Analyst Opinion

46

  • Ratings consensus is Sell

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

AREV Life Sciences Global Corp.

Currency

CAD

Beta

2.013569

Vol Avg

6712

Ceo

Mr. Michael Withrow

Cik

Cusip

Exchange

Canadian Sec

Full Time Employees

Industry

Drug Manufacturers—Specialty & Generic

Sector

Healthcare

Ipo Date

Address

18 - 91 Golden Drive

City

Coquitlam

State

BC

Country

CA

Zip

V3K 6R2

Phone

604 803 8439

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies